Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance

Circulation

Volumn 106, Issue 13, 2002, Pages 1646-1651

  Sorensen, Morten B ^a,b,c   Collins, Peter ^b   Ong, Paul J L ^b   Webb, Carolyn M ^b   Hayward, Christopher S ^b   Asbury, Elizabeth A ^b   Gatehouse, Peter D ^a   Elkington, Andrew G ^a   Yang, Guang Z ^a   Kubba, Ali ^d   Pennell, Dudley J ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Endothelium; Heart disease; Magnetic resonance imaging; Women

Indexed keywords

ESTRADIOL; GLYCERYL TRINITRATE; MEDROXYPROGESTERONE ACETATE;

ADULT; AMENORRHEA; ARTERY BLOOD FLOW; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; FEMALE; HEART DISEASE; HUMAN; MENSTRUAL CYCLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREMENOPAUSE; PRIORITY JOURNAL; REPRODUCIBILITY; VASODILATATION;

ADULT; AMENORRHEA; BRACHIAL ARTERY; DELAYED-ACTION PREPARATIONS; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NITROGLYCERIN; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TIME; ULTRASONOGRAPHY, INTERVENTIONAL; VASCULAR DISEASES; VASOMOTOR SYSTEM;

EID: 0037167721     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000030940.73167.4E     Document Type: Article

References (27)

1. Clark MK, Sowers M, Levy BT, et al. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril. 2001;75:871-877.
2. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41:381-390.
3. Miller L, Patton DL, Meier A, et al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol. 2000;96:431-439.
4. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception., BMJ. 1991;303:13-16.
5. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
6. Miyagawa K, Rosch J, Stanczyk F, et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
7. Kawano H, Motoyama T, Hirai N, et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. Am J Cardiol. 2001;87:238-240.
8. Frederiksen MC. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med. 1996;41:414-418.
9. Furchgott RF, Zawadzki JF. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980:288:373-376.
10. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987:327:524-526.
11. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
12. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circtdation. 2000;101:948-954.
13. Celermajer DS, Sorensen KE. Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
14. Kobayashi H, Yoshida A, Kobayashi M. et al. Non-invasive detection of endothelial dysfunction with 30 MHz transducer. Lancet, 1996;347:1336-1337.
15. Hardie KL. Kinlay S, Hardy DB. et al. Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function. Aust N Z J Med. 1997:27:649-652.
16. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21:1387-1396.
17. Ong PJ, Dean TS, Hayward CS, et al. Effect of fat and carbohydrate consumption on endothelial function. Lancet. 1999;354:2134.
18. Ong PJ, Linardou H, Graham HA, et al. Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. Am Heart J. 2001;142:E6.
19. Yim SF, Lau TK, Sahota DS, et al. Prospective randomized study of the effect of "add-back" hormone replacement on vascular function during treatment with gonadotropin-releasing hormone agonists. Circulation. 1998;98:1631-1635.
20. John S, Jacobi J, Schlaich MP, et al. Effects of oral contraceptives on vascular endothelium in premenopausal women. Am J Obstet Gynecol. 2000;183:28-33.
21. Collins P. Webb C. Estrogen hits the surface. Nat Med. 1999:5:1130-1131.
22. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998:98:1158-1163.
23. Enk L, Landgren BM, Lindberg UB. et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res. 1992;24:85-89.
24. Berenson AB. Radecki CM, Grady JJ. et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:576-582.
25. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception. 1998:57:315-324.
26. Blum A, Hathaway L, Mincemoyer R. et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation. 2000;101:2160-2164.
27. Koh KK, Blum A. Hathaway L, et al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation. 1999;100:1851-1857.